EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieLeserbriefOpen Access · CC BY-NC-ND 4.0

Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial

Rajna Golubic iD, Mouhamad Hussein Ismail, Masa Josipovic, Jane Kennet, Alfonso Galderisi, Mark L Evans iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15176 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Rajna Golubic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Glucose, Insulin Resistance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Diabetes Research and Wellness Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Evidence from mouse models suggests that brain serotonergic pathways control blood glucose. We hypothesized that sumatriptan (5HT 1B ‐receptor agonist) would alter glucose homeostasis in humans. Materials and Methods We conducted a two‐visit random‐order double‐blinded placebo‐controlled cross‐over trial in 10 overweight adults that were otherwise healthy. Participants received sumatriptan (single dose, 100 mg) or placebo before undergoing a 60‐min intravenous glucose tolerance test, followed by a 120‐min hyperinsulinaemic euglycaemic clamp.

Results

Glucose excursion was greater during intravenous glucose tolerance test with sumatriptan compared with placebo [iAUC 0‐60 min 316 (268‐333) vs. 251 (197‐319) min/mmol/L p = .047]. This was probably explained by a combination of reduced circulating insulin levels [iAUC 0‐10 min 1626 (1103‐2733) vs. 2336 (1702‐3269) min/pmol/L, p = .005], reduced insulin sensitivity [M/I‐value 2.11 (1.15, 4.05) vs. 3.03 (1.14, 4.90) mg/kg/min per pmol/L, p = .010] and glucose effectiveness [S G 0.17 (0.12, 0.21) vs. 0.22 (0.18, 0.65)/min, p = .027].

Conclusions

5HT 1B receptors have a glucoregulatory role in humans, probably acting on insulin secretion, insulin sensitivity and glucose effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseInsulin ResistanceAdultAnimalsMiceHumansOverweightInsulin SecretionSumatriptanSerotoninCross-Over StudiesInsulinBlood GlucoseDouble-Blind Method

Stichwörter der Autor:innen

beta cell functiondrug mechanismeffectivenessglycaemic controlinsulin secretionrandomised trial

Substanzen

GlucoseSumatriptanSerotoninInsulinBlood Glucose

Autor:innen und Institutionen

  • Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Department of Cell Biology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Pediatric Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Rajna Golubic, Mark L Evans

Förderung

  • Diabetes Research and Wellness Foundation

Zitieren

APA

Golubic, R., Hussein Ismail, M., Josipovic, M., Kennet, J., Galderisi, A., & Evans, M. L. (2023). Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15176

Vancouver

Golubic R, Hussein Ismail M, Josipovic M, Kennet J, Galderisi A, Evans ML. Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15176

BibTeX
@article{Golubic2023,
  author = {Golubic, Rajna and Hussein Ismail, Mouhamad and Josipovic, Masa and Kennet, Jane and Galderisi, Alfonso and Evans, Mark L},
  title = {Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15176}
}
Kostenlos starten →